As of 10:41 on March 12, 2025, the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) fell by 0.10%. In terms of constituent stocks, 3SBio (01530) led the rise of 8.10%, XtalPi-P (02228) rose 6.59%, and Federated Pharmaceutical (03933) rose 2.10%; GenScript Biotech (01548) led the decline by 2.81%, InnoCare (09969) fell by 2.20%, and JD Health (06618) fell by 1.96%. Hong Kong stock pharmaceutical ETF (159718) rose more than 1% intraday, the latest price was 0.68 yuan, and the intraday turnover has reached 30.2446 million yuan, with a turnover rate of 13.58%, and the market is actively trading.

As of 10:40 on March 12, 2025, the CSI Pharmaceutical and Medical Device Innovation Index (931484) fell by 0.60%. In terms of constituent stocks, Nhwa Pharmaceutical (002262) led by 6.52%, Aibo Medical (688050) rose 1.79%, and Yirui Technology (688301) rose 0.39%; Kelun Pharmaceutical (002422) led the decline by 3.21%, Aimeike (300896) fell by 2.54%, and Haisco (002653) fell by 2.17%. Medical Innovation ETF (516820) fell 0.29%, the latest price was 0.34 yuan, and the intraday turnover has reached 23.7371 million yuan, with a turnover rate of 1.31%.

In the long run, as of March 11, 2025, Hong Kong stock pharmaceutical ETFs have risen by 1.05% in the past week, ranking 1/4 of comparable funds. Healthcare Innovation ETF has risen 0.59% over the past 1 week.

In terms of scale, the latest scale of medical innovation ETF reached 1.813 billion yuan, a new high in recent March.

In terms of fund inflow, the latest net outflow of medical innovation ETF was 6.4605 million yuan. In the long run, there have been 3 net inflows of funds in the past 5 trading days, with a total of 32.4726 million yuan of "gold absorption", and an average daily net inflow of 6.4945 million yuan.

The data shows that leveraged funds continue to be deployed. The latest financing purchase amount of medical innovation ETF reached 7.9338 million yuan, and the latest financing balance reached 87.4197 million yuan.

Huawei's entry into the game accelerates the implementation of large medical models, and Huawei officially established a medical and health corps to focus on AI-assisted diagnosis and clinical application of medical large models, aiming to solve the technical and ecological bottlenecks in the implementation of medical AI.

Founder Securities said that it is recommended to configure the direction of "technological breakthrough certainty (AI pharmaceutical) + rigid demand for infrastructure (equipment/data) + service supply to fee payment to form a complete business chain (health management)". 1) AI+ Pharmaceutical: The world's first AI-led design of idiopathic pulmonary fibrosis drug INS018_055 has entered phase II clinical trials, and its preclinical cycle has been compressed to 30 months, and domestic companies are deeply involved in the global innovation chain; 2) AI+ basic research: multi-omics (genomics/proteomics, etc.) data-driven breakthroughs in disease mechanisms, and the substitution of domestic scientific research equipment is accelerated; 3) AI + diagnosis and treatment: revolution in diagnostic efficiency + leap in surgical accuracy; 4) AI + health management: The chronic disease management market has been digitally reconstructed, and the clarity of the payer (medical insurance/commercial insurance) has been enhanced.

The CSI Hong Kong Stock Connect Medical and Health Composite Index selects 50 securities of listed companies in the medical and health industry with good liquidity and large market capitalization from the Hong Kong Stock Connect as index samples to reflect the overall performance of the securities of medical and health listed companies within the scope of Hong Kong Stock Connect.

According to the data, as of February 28, 2025, the top 10 weighted stocks of the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) are BeiGene (06160), WuXi Biologics (02269), Innovent Biologics (01801), Akeso Biologics (09926), JD Health (06618), CSPC Pharmaceutical Group (01093), Sino Biopharma (01177), Ali Health (00241), Zai Lab (09688), Sinopharm ( 01099), the top 10 weighted stocks accounted for 59.55% of the total.

Hong Kong Pharmaceutical ETF (159718), OTC Connect (Ping An CSI Hong Kong Pharmaceutical ETF Connect A: 019598; Ping An CSI Hong Kong Pharmaceutical ETF Connect C: 019599).

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of February 28, 2025, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec (603259), Mindray Medical (300760), Hengrui Pharmaceutical (600276), Aier Ophthalmology (300015), United Imaging Healthcare (688271), Kelun Pharmaceutical (002422), Changchun High-tech (000661), Huadong Medicine (000963), and Zhifei Biotechnology (300122). ), Pharmaron (300759), the top 10 weighted stocks together accounted for 66.9%.